KUS121, a novel VCP modulator, attenuates atherosclerosis development by reducing ER stress and inhibiting glycolysis through the maintenance of ATP levels in endothelial cells
KUS121 can be a new therapeutic option for atherosclerotic diseases by maintaining intracellular ATP levels, leading to the attenuation of ER stress and glycolysis in plaque endothelium.
Authors
- Koh Ono (ORCID: https://orcid.org/0000-0002-4163-980X)
- Chiharu Otani
- Shuhei Tsuji (ORCID: https://orcid.org/0000-0002-6297-5642)
- Tomohiro Yamasaki (ORCID: https://orcid.org/0000-0002-9858-9049)
- Miyako Imanaka
- Yasuhiro Nakashima (ORCID: https://orcid.org/0000-0003-3025-723X)
- Takahiro Horie (ORCID: https://orcid.org/0000-0002-6766-750X)
- Fuquan Zou
- Sijia Xu
- Akira Kakizuka (ORCID: https://orcid.org/0000-0003-3513-0334)
- Naoya Sowa
- Osamu Baba (ORCID: https://orcid.org/0000-0002-5891-2323)
- Keita W. Suzuki (ORCID: https://orcid.org/0000-0001-9037-2964)
- Eitaro Kume (ORCID: https://orcid.org/0000-0002-8913-6814)
- Kazuki Matsushita
- Kayo Kimura
- Hidenori Kojima (ORCID: https://orcid.org/0009-0003-2705-2329)
- Qiuxian Qian
Institutions
- Kyoto University (JP)
- Kyoto Medical Center (JP)
- Kyoto University Hospital (JP)
Publication Details
- Journal
- Atherosclerosis
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1016/j.atherosclerosis.2025.119223
- Primary Topic
- Endoplasmic Reticulum Stress and Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00